Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The researchers reported that QR678 Neo® combined with intralesional steroids significantly improved hair regrowth and patient satisfaction in treating alopecia areata compared to steroids alone.

This review discusses emerging evidence on azathioprine's efficacy and safety for severe alopecia areata, reporting sustained response in many patients but emphasizing the need for controlled trials.

In a case-series study, researchers reported significant hair regrowth in Alopecia Areata patients after three months of treatment with a topical preparation called Freezia cream, which was developed by specialized medical professionals and approved by the Iraqi Ministry of Health.

New therapy helps treat hair loss.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This study evaluated current treatments for pediatric alopecia areata and found that high potency topical steroids had the strongest supporting evidence, with promising results also observed for anthralin ointment and other treatments in lower-grade studies.

This study found that among the tested analogs, compound 4e was the most effective in inhibiting wax esters in vivo in the Golden Syrian hamster ear model.

Apremilast may help treat hair loss in alopecia areata.

In this case report, two Persian cats with Lynxacarus radovskyi fur mites and symptoms like mild alopecia and pruritus fully recovered after receiving selamectin spot-on treatment monthly for three months.

This case report on a 13-year-old boy with monilethrix observed slight improvement after a two-month trial of oral N-acetyl cysteine, but overall hair density did not improve further.

This study found that nano-sized minoxidil formulations significantly increased skin penetration and follicular drug delivery for alopecia areata treatment, compared to conventional ethanol-based solutions, and demonstrated effective controlled release over six hours.

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

This study found that niosomal aminexil was more clinically effective for hair growth than conventional aminexil solutions, and that niosomes facilitated aminexil penetration through rat skin without propylene glycol.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

In this study, in silico analysis identified Saponin Re and Emodin as promising candidates for topical treatment of androgenetic alopecia, with Biochanin A having the most favorable safety profile among the tested compounds.

Tigason improved hair growth in a boy with monilethrix without side effects.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

This study evaluated Korean herbal compounds in silico and identified Biochanin A, Saponin Re, and Emodin as potential topical treatments for androgenetic alopecia, each with specific safety and efficacy considerations.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

In this study, intralesional pentoxifylline was found to be an effective and well-tolerated treatment for alopecia areata, showing significant improvements in hair loss with minimal side effects and a low recurrence rate among the 50 patients tested over 12 weeks.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

In this study, researchers explored whether minoxidil, a common treatment for androgenetic alopecia, may have estrogenic activity and found preliminary evidence suggesting it could act as a partial agonist of Estrogen Receptor α (ERα).